APA (7th ed.) Citation

LQM, C., R, H., S, G., A, M., R, M., M, T., . . . TY, S. (2016). Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34(32), 3838. https://doi.org/10.1200/JCO.2016.68.1478

Chicago Style (17th ed.) Citation

LQM, Chow, et al. "Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent And/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 34, no. 32 (2016): 3838. https://doi.org/10.1200/JCO.2016.68.1478.

MLA (9th ed.) Citation

LQM, Chow, et al. "Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent And/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 34, no. 32, 2016, p. 3838, https://doi.org/10.1200/JCO.2016.68.1478.